Lyka Labs (BOM:500259) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

What is Lyka Labs FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Lyka Labs's Free Cash Flow for the three months ended in Dec. 2023 was ₹0 Mil. Lyka Labs's Revenue for the three months ended in Dec. 2023 was ₹326 Mil. Therefore, Lyka Labs's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Lyka Labs's current FCF Yield % is 0.19%.

The historical rank and industry rank for Lyka Labs's FCF Margin % or its related term are showing as below:

BOM:500259' s FCF Margin % Range Over the Past 10 Years
Min: -1.29 Med: 12.37 Max: 39.07
Current: 0.76

During the past 13 years, the highest FCF Margin % of Lyka Labs was 39.07%. The lowest was -1.29%. And the median was 12.37%.

BOM:500259's FCF Margin % is ranked better than
79.77% of 1048 companies
in the Biotechnology industry
Industry Median: -144.01 vs BOM:500259: 0.76

Lyka Labs FCF Margin % Historical Data

The historical data trend for Lyka Labs's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lyka Labs FCF Margin % Chart

Lyka Labs Annual Data

Trend

Mar13

Jun14

Jun15

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

FCF Margin %

Get a 7-Day Free Trial

34.01

7.62

11.24

39.07

0.87

Lyka Labs Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Lyka Labs's FCF Margin %

For the Biotechnology subindustry, Lyka Labs's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lyka Labs's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lyka Labs's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Lyka Labs's FCF Margin % falls into.

Lyka Labs FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Lyka Labs's FCF Margin for the fiscal year that ended in Mar. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Mar. 2023 )	/	Revenue (A: Mar. 2023 )
	=	7.672	/	883.39
	=	0.87 %

Lyka Labs's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	0	/	325.638
	=	0.00 %

Lyka Labs FCF Margin % Related Terms

Thank you for viewing the detailed overview of Lyka Labs's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lyka Labs (BOM:500259) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lyka Labs Ltd (BOM:500259) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

LYKALABS:India

Address

30, Forjett Street, Near Bhatia Hospital, Ground floor, Spencer Building (Block B & C), Grant Road (West), Mumbai, MH, IND, 400036

Website

http://www.lykalabs.com

Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment viz. pharmaceuticals. The Company has presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.

Lyka Labs (BOM:500259) Headlines

No Headlines